Icon times
Sanofi India Q1 FY22 Results Analysis

Sanofi India Q1 FY22 Results Analysis

Published on 29 July 2021 .Views 251 .Comments 0
Share On
'Sanofi India delivered terrific growth in EBITDA & PAT of 28% & 30% on YOY Basis respectively along with increase in EBITDA & PAT margins despite average growth in sales of 11% riding on savings in other expenses along with YOY decline in Employee benefit expenses.'
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 9,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded

premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
Chat with InvestYadnya